Summary of Wuxi Biologics Conference Call Company Overview - **Company**: Wuxi Biologics - **Industry**: Biologics Contract Development and Manufacturing Organization (CDMO) Key Points Growth Drivers - **New Modalities**: Wuxi Bio is expected to benefit from the growth of new modalities, specifically antibody-drug conjugates (ADC) and bi/multi-specific antibodies (b/msAb), which are projected to grow at a CAGR of 43% from 2020 to 2024, surpassing traditional monoclonal antibodies (mAbs) which have a CAGR of 17% [2][11] - **Revenue Contribution**: Preliminary revenue from Wuxi XDC, a subsidiary, accounted for approximately 27% of Wuxi Bio's total revenue in H125, indicating strong growth potential [2] Market Position - **China's Leadership**: China is leading in the global R&D pipeline for new modalities, with 46% of b/msAb and 52% of ADC originating from the country. This positions Wuxi Bio favorably to capture a significant share of the market [3][22] - **Out-licensing Trends**: Chinese biopharma's out-licensing activities are robust, with 32% of global total deal value attributed to China, and 45% of this value coming from b/msAb and ADC [3][28] Financial Performance - **Revenue Projections**: Revenue is expected to grow from RMB 21.3 billion in 2025 to RMB 40.4 billion by 2029, with a gross margin improvement from 41.3% to 45.0% over the same period [6][51] - **Earnings Growth**: Net profit is projected to increase significantly, with estimates for 2025 showing a net profit of RMB 4.74 billion, rising to RMB 9.45 billion by 2029 [6][46] Valuation and Market Sentiment - **Price Target**: The price target has been raised to HK$41.20 from HK$20.30, reflecting a potential upside based on the company's growth prospects in new modalities [5][47] - **Current Trading Metrics**: As of August 7, 2025, Wuxi Bio is trading at HK$30.02, which is below the median P/E ratio of 25x for comparable Chinese CRO companies [7][49] Competitive Advantages - **Technological Edge**: Wuxi Bio utilizes advanced platforms such as WuxiBody bispecific and Wuxi DARx ADC, which enhance R&D efficiency and product quality [39][43] - **Flexible Capacity**: The company has a geographically diversified capacity and employs 100% disposable reactors, allowing for flexible scaling of production to meet demand [4][39] Risks and Considerations - **Geopolitical Factors**: While geopolitical uncertainties have previously impacted demand, the company has shown resilience, with preliminary revenue growth of 16% YoY in H125 [14] - **Market Competition**: The competitive landscape remains intense, particularly in the monoclonal antibody segment, but Wuxi Bio's focus on new modalities positions it well for future growth [44] Conclusion - **Long-term Outlook**: Wuxi Biologics is poised for significant growth driven by new modalities, strong market positioning in China, and advanced technological capabilities. The current valuation does not fully reflect its growth potential, making it an attractive investment opportunity [12][21]

Group 1 - The core viewpoint of the article highlights the recent stock performance of WuXi Biologics, which experienced a 2.0% decline, trading at 29.42 yuan per share with a transaction volume of 926 million yuan [1] - WuXi Biologics is recognized as a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - In 2016, the company held a significant 48% market share in China's biologics R&D market and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - As of the 2024 annual report, WuXi Biologics reported total revenue of 18.675 billion yuan and a net profit of 3.356 billion yuan [2] - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 19 [2]

Core Viewpoint - WuXi Biologics is a global leader in the biopharmaceutical CDMO (Contract Development and Manufacturing Organization) sector, leveraging an integrated platform to drive growth [1] Group 1: Business Model and Performance - The company pioneered the CRDMO (Contract Research, Development, and Manufacturing) model, offering comprehensive services from drug discovery to commercial production, which enhances customer retention by locking in partnerships 5-10 years in advance [1] - In 2024, the company is expected to serve over 600 clients, including the top 20 multinational pharmaceutical companies, with a core employee retention rate of 95.8%, ensuring operational stability [1] - The company’s revenue is projected to reach 18.7 billion yuan in 2024, reflecting a 9.3% increase, with a net profit of 3.36 billion yuan [1] Group 2: Growth Drivers - Non-COVID-related business is expected to grow significantly, with a 13.1% year-on-year increase in 2024, and a CAGR of 42% from 2017 to 2024, indicating a healthy business structure [2] - The company has a substantial backlog of unfulfilled orders, totaling approximately 18.5 billion USD, with a compound growth rate of 69.6% from 2016 to 2024 [2] - The company’s pipeline includes 194 ADC-related projects in 2024, a 35.7% increase year-on-year, indicating strong growth in complex therapy production [3] Group 3: Market Position and Future Outlook - The global biopharmaceutical market is expanding, with China holding an 18.8% share, projected to reach 162.8 billion USD by 2030, benefiting the CDMO market [2] - The company’s production capacity is expected to reach 580,000 liters by 2026, potentially supporting profits of approximately 7.8 billion yuan at full capacity [3] - Compared to international peers, the company has a significant valuation advantage, with a current PE ratio of 35.2X, lower than that of global leaders [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 6,000,000,000 | USD | 0.000008333333 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 6,000,000,000 | U ...

Core Viewpoint - The China Securities Hong Kong 100 Pharmaceutical and Health Index has shown significant growth, with a 22.21% increase over the past month, 41.09% over the past three months, and a remarkable 96.31% year-to-date [1]. Group 1: Index Performance - The China Securities Hong Kong 100 Pharmaceutical and Health Index is currently at 1134.87 points [1]. - The index is classified based on the China Securities Industry Classification Standard, with a base date of December 31, 2004, set at 1000.0 points [1]. Group 2: Market Composition - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100.00% allocation [1]. - The industry composition of the index includes: - Chemical drugs: 54.47% - Biological drugs: 19.42% - Pharmaceutical and biotechnology services: 14.91% - Medical commerce and services: 11.20% [1]. Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments under special circumstances [2].

Investment Rating - The report assigns a "Buy" rating for WuXi Biologics (2269 HK) as part of its initial coverage [4] Core Insights - WuXi Biologics is a global leader in the biopharmaceutical CDMO (Contract Development and Manufacturing Organization) sector, leveraging an integrated platform to drive growth [1][3] - The company has established a comprehensive CRDMO (Contract Research, Development, and Manufacturing Organization) model, providing end-to-end services from drug discovery to commercial production, which enhances customer retention and operational stability [1][3] - The non-COVID business has shown strong growth, with a 13.1% year-on-year increase in 2024, indicating a healthy business structure despite a slowdown in overall revenue growth [49] Summary by Sections 1. Company Overview - WuXi Biologics has developed a one-stop CRDMO service platform, serving over 600 global clients, including the top 20 multinational pharmaceutical companies, with a core employee retention rate of 95.8% [1][21][20] - The company has a global manufacturing network with 9 production bases and 7 development centers across China, Ireland, Germany, and Singapore, supporting its full industry chain service capabilities [1][27] 2. Market Growth and Opportunities - The global biopharmaceutical market is expanding, with China expected to capture a 22.2% share by 2030, driven by the rise of biopharmaceuticals and CDMO services [3][50][53] - The ADC (Antibody-Drug Conjugates) and bispecific antibodies are emerging therapies that are expected to significantly benefit WuXi Biologics as the CDMO market continues to grow [3][54] 3. Financial Performance - WuXi Biologics has demonstrated robust growth, with a revenue CAGR of 36.0% from 2019 to 2024, reaching 18.68 billion yuan in 2024, despite a slight decline in growth rate [6][29] - The company’s net profit for 2024 is projected to be 3.36 billion yuan, with a gross margin of 41.0% [10][45] 4. Future Projections - The report forecasts revenues of 21.47 billion yuan, 23.65 billion yuan, and 25.91 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 4.48 billion yuan, 4.99 billion yuan, and 5.36 billion yuan [8][10] - The company is expected to benefit from a strong order backlog, with approximately 18.5 billion USD in unfulfilled orders as of December 31, 2024, indicating a solid foundation for future revenue growth [6][28] 5. Competitive Positioning - WuXi Biologics is positioned favorably compared to international peers, with a current PE ratio of 35.2X, significantly lower than that of global leaders like Lonza and Samsung Biologics [7][72] - The report highlights the potential for valuation recovery as the company continues to expand its market share and capitalize on the growing demand for biopharmaceutical services [66][70]

Group 1 - The core viewpoint of the article highlights the recent stock performance of WuXi Biologics, which experienced a decline of 2.01% on August 6, trading at 31.22 HKD per share with a transaction volume of 4.38 billion HKD [1] - WuXi Biologics is recognized as a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - As of 2016, the company held a significant 48% market share in China's biologics R&D market and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - For the fiscal year ending 2024, WuXi Biologics reported total revenue of 18.675 billion HKD and a net profit of 3.356 billion HKD [1] - The company is set to disclose its interim report for the fiscal year 2025 on August 19 [1]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical and Health Comprehensive Index has shown significant growth, with a year-to-date increase of 85.26% [1]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 2.51%, closing at 3658.84 points with a trading volume of 24.507 billion yuan [1]. - Over the past month, the Hong Kong Stock Connect Medical and Health Comprehensive Index has risen by 24.02%, and over the last three months, it has increased by 47.29% [1]. Group 2: Index Composition - The index comprises 50 liquid and large-cap medical and health industry companies listed within the Hong Kong Stock Connect, reflecting the overall performance of these securities [1]. - The index was established on November 14, 2014, with a base point of 3000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: - Innovent Biologics (10.25%) - WuXi Biologics (9.23%) - BeiGene (8.95%) - CanSino Biologics (8.12%) - China Biologic Products (5.97%) - CSPC Pharmaceutical Group (5.77%) - JD Health (4.52%) - 3SBio (4.19%) - Hansoh Pharmaceutical (3.0%) - WuXi AppTec (2.85%) [1]. Group 4: Market and Sector Allocation - The index's holdings are entirely composed of securities listed on the Hong Kong Stock Exchange, with a 100% allocation to the medical and health sector [1].

天眼查资料显示，无锡药明生物技术股份有限公司，成立于2010年，位于无锡市，是一家以从事研究和 试验发展为主的企业。企业注册资本891577万人民币。通过天眼查大数据分析，无锡药明生物技术股份 有限公司共对外投资了12家企业，参与招投标项目39次，财产线索方面有商标信息30条，专利信息128 条，此外企业还拥有行政许可370个。 本文源自：金融界 作者：情报员 金融界2025年8月1日消息，国家知识产权局信息显示，无锡药明生物技术股份有限公司申请一项名 为"一次性配液场景中的配液方法、配液系统、控制设备和存储介质"的专利，公开号 CN120393847A， 申请日期为 2025年04月。 专利摘要显示，本发明公开了一次性配液场景中的配液方法、配液系统、控制设备和存储介质。其中方 法包括：在任一液体注入阶段中，获取所述液体注入阶段的期望液体重量，以及所述液体注入阶段的实 际液体重量；在所述实际液体重量满足所述期望液体重量对应的第一阈值条件的情况下，基于多时段注 入模式控制所述出液口向所述配制袋注入液体：在任一注入时段，在所述出液口的注入时长达到所述注 入时段的设定时长时，控制所述出液口关闭；在满足间隔条件时，控 ...

金融界2025年8月1日消息，国家知识产权局信息显示，无锡药明生物技术股份有限公司取得一项名 为"膜包清洁和使用方法"的专利，授权公告号CN116116230B，申请日期为2023年04月。 天眼查资料显示，无锡药明生物技术股份有限公司，成立于2010年，位于无锡市，是一家以从事研究和 试验发展为主的企业。企业注册资本891577万人民币。通过天眼查大数据分析，无锡药明生物技术股份 有限公司共对外投资了12家企业，参与招投标项目39次，财产线索方面有商标信息30条，专利信息128 条，此外企业还拥有行政许可370个。 本文源自：金融界 作者：情报员 ...